Whereas MED12 mutations in other positions have been identified in prostate and adrenocortical carcinomas in much lower frequency (5%) 8,9, MED12 exon 2 mutations in other tumors have been rare events. The gene discussed is MED12; the disease is adrenal cortex carcinoma.